Latest News and Press Releases

Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care...

Media Release Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patientsExpansion based on safety and strong initial efficacy...

Media Release 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting...

Media Release Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and will help inform a BLA and MAAHR+/HER2-neg/low metastatic breast cancer (MBC) patient population has...

Media Release 20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination therapy study of efti with standard-of-care combination of anti-PD-1 therapy...

Media Release Second US FDA Fast Track designation granted to eftilagimod alpha (efti) supporting planned late-stage development in 1st line non-small cell lung cancer (1L NSCLC)Compelling Phase II...

SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...

Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patientsPatient population...

Media Release First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi Biologics SYDNEY, AUSTRALIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM;...

Media Release SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing...